Literature DB >> 15282268

Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.

Matteo Marti1, Flora Mela, Carlo Veronesi, Remo Guerrini, Severo Salvadori, Mauro Federici, Nicola B Mercuri, Anna Rizzi, Gianfranco Franchi, Lorenzo Beani, Clementina Bianchi, Michele Morari.   

Abstract

A multidisciplinary approach was followed to investigate whether the opioid-like peptide nociceptin/orphanin FQ (N/OFQ) regulates the nigrostriatal dopaminergic pathway and motor behavior. Nigrostriatal dopaminergic cells, which express N/OFQ peptide (NOP) receptors, are located in the substantia nigra pars compacta and extend their dendrites in the substantia nigra pars reticulata, thereby modulating the basal ganglia output neurons. In vitro electrophysiological recordings demonstrated that N/OFQ hyperpolarized the dopaminergic cells of the substantia nigra pars compacta and inhibited their firing activity. In vivo dual-probe microdialysis showed that N/OFQ perfused in the substantia nigra pars reticulata reduced dopamine release in the ipsilateral striatum, whereas UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ(1-13)-NH2) (a selective NOP receptor peptide antagonist) stimulated it. N/OFQ microinjected in the substantia nigra pars reticulata impaired rat performance on a rotarod apparatus, whereas UFP-101 enhanced it. Electromyography revealed that N/OFQ and UFP-101 oppositely affected muscle tone, inducing relaxation and contraction of triceps, respectively. The selective NOP receptor nonpeptide antagonist J-113397 (1-[3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one), either injected intranigrally or given systemically, also elevated striatal dopamine release and facilitated motor activity, confirming that these effects were caused by blockade of endogenous N/OFQ signaling. The inhibitory role played by endogenous N/OFQ on motor activity was additionally strengthened by the finding that mice lacking the NOP receptor gene outperformed wild-type mice on the rotarod. We conclude that NOP receptors in the substantia nigra pars reticulata, activated by endogenous N/OFQ, drive a physiologically inhibitory control on motor behavior, possibly via modulation of the nigrostriatal dopaminergic pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282268      PMCID: PMC6729727          DOI: 10.1523/JNEUROSCI.0987-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  61 in total

1.  Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).

Authors:  H Kawamoto; S Ozaki; Y Itoh; M Miyaji; S Arai; H Nakashima; T Kato; H Ohta; Y Iwasawa
Journal:  J Med Chem       Date:  1999-12-16       Impact factor: 7.446

2.  A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397.

Authors:  S Ozaki; H Kawamoto; Y Itoh; M Miyaji; Y Iwasawa; H Ohta
Journal:  Eur J Pharmacol       Date:  2000-01-17       Impact factor: 4.432

Review 3.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats.

Authors:  A Di Giannuario; S Pieretti; A Catalani; A Loizzo
Journal:  Neurosci Lett       Date:  1999-09-17       Impact factor: 3.046

5.  Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis.

Authors:  N P Murphy; N T Maidment
Journal:  J Neurochem       Date:  1999-07       Impact factor: 5.372

6.  Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.

Authors:  R Guerrini; G Caló; R Bigoni; A Rizzi; K Varani; G Toth; S Gessi; E Hashiba; Y Hashimoto; D G Lambert; P A Borea; R Tomatis; S Salvadori; D Regoli
Journal:  J Med Chem       Date:  2000-07-27       Impact factor: 7.446

7.  GABA(A) and GABA(B) antagonists differentially affect the firing pattern of substantia nigra dopaminergic neurons in vivo.

Authors:  C A Paladini; J M Tepper
Journal:  Synapse       Date:  1999-06-01       Impact factor: 2.562

8.  Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist.

Authors:  C Polidori; G Calo; R Ciccocioppo; R Guerrini; D Regoli; M Massi
Journal:  Psychopharmacology (Berl)       Date:  2000-03       Impact factor: 4.530

9.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

Authors:  F Jenck; J Wichmann; F M Dautzenberg; J L Moreau; A M Ouagazzal; J R Martin; K Lundstrom; A M Cesura; S M Poli; S Roever; S Kolczewski; G Adam; G Kilpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

10.  Pertussis toxin lesions of the rat substantia nigra block the inhibitory effects of the gamma-hydroxybutyrate agent, S(-)HA-966 without affecting the basal firing properties of dopamine neurons.

Authors:  P D Shepard; S T Connelly
Journal:  Neuropsychopharmacology       Date:  1999-11       Impact factor: 7.853

View more
  27 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

3.  Activation of nociceptin/orphanin FQ peptide receptors disrupts visual but not auditory sensorimotor gating in BALB/cByJ mice: comparison to dopamine receptor agonists.

Authors:  Aurelia Ces; David Reiss; Ondine Walter; Jürgen Wichmann; Eric P Prinssen; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

4.  Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Authors:  Omar S Mabrouk; Riccardo Viaro; Mattia Volta; Ada Ledonne; Nicola Mercuri; Michele Morari
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 5.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

6.  Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Authors:  Ludovico Arcuri; Salvatore Novello; Martina Frassineti; Daniela Mercatelli; Clarissa Anna Pisanò; Ilaria Morella; Stefania Fasano; Blair V Journigan; Michael E Meyer; Willma E Polgar; Riccardo Brambilla; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2018-01-31       Impact factor: 8.739

7.  NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Authors:  Anna Maria Borruto; Yannick Fotio; Serena Stopponi; Gloria Brunori; Michele Petrella; Francesca Felicia Caputi; Patrizia Romualdi; Sanzio Candeletti; Rajesh Narendran; Linda M Rorick-Kehn; Massimo Ubaldi; Friedbert Weiss; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

Review 8.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

Review 9.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

10.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.